Novartis: Q2 net sales up 9% YoY at $12.9B

Wednesday, 21. July 2021 07:05

Novartis unveiled on Wednesday that its net sales for the second quarter of 2021 stood at $12.9 billion increasing 9% when compared to the same period last year.

Earnings per share (EPS) surged 49% year on year to $1.29, while net income reached $2.9 billion increasing 49% per annum. At the same time, both core EPS and core net income gained 16% and 14% respectively to reach $1.66 and $3.7 billion in the three-month period. Lastly, operating income rose 41% to $3.5 billion, while core operating was 13% up to $4.3 billion.

Novartis CEO Vas Narasimhan commented on the results: "Novartis delivered a strong second quarter, driven by the momentum of our key growth brands, including Cosentyx, Entresto, Zolgensma, our Oncology portfolio and the launch of Kesimpta which continues to accelerate. Looking ahead, we reconfirm our full-year guidance and our commitment to drive long-term accretive growth."

Related Links: Novartis AG
Author:
Breaking the News / OL